CA2072891C - Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity - Google Patents

Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity

Info

Publication number
CA2072891C
CA2072891C CA002072891A CA2072891A CA2072891C CA 2072891 C CA2072891 C CA 2072891C CA 002072891 A CA002072891 A CA 002072891A CA 2072891 A CA2072891 A CA 2072891A CA 2072891 C CA2072891 C CA 2072891C
Authority
CA
Canada
Prior art keywords
molecule
amino acid
carboxyl
recognition
carboxyl terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002072891A
Other languages
English (en)
French (fr)
Other versions
CA2072891A1 (en
Inventor
Ira Pastan
Vijay Chaudhary
David J. Fitzgerald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2072891A1 publication Critical patent/CA2072891A1/en
Application granted granted Critical
Publication of CA2072891C publication Critical patent/CA2072891C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002072891A 1990-01-02 1990-12-27 Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity Expired - Fee Related CA2072891C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45963590A 1990-01-02 1990-01-02
US459,635 1990-01-02
PCT/US1990/007421 WO1991009949A1 (en) 1990-01-02 1990-12-27 Target-specific, cytotoxic, recombinant pseudomonas exotoxin

Publications (2)

Publication Number Publication Date
CA2072891A1 CA2072891A1 (en) 1991-07-03
CA2072891C true CA2072891C (en) 1999-12-21

Family

ID=23825594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002072891A Expired - Fee Related CA2072891C (en) 1990-01-02 1990-12-27 Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity

Country Status (5)

Country Link
EP (1) EP0509056A4 (de)
JP (1) JP2610740B2 (de)
AU (1) AU644139B2 (de)
CA (1) CA2072891C (de)
WO (1) WO1991009949A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
NZ237758A (en) * 1990-04-17 1992-12-23 Shell Int Research (phenylalkyl) triphenylphosphonium salt derivatives and fungicidal compositions
DE69131449T2 (de) * 1990-05-11 1999-11-25 The United States Of America, Represented By The Secretary Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity

Also Published As

Publication number Publication date
EP0509056A1 (de) 1992-10-21
WO1991009949A1 (en) 1991-07-11
EP0509056A4 (en) 1993-02-17
CA2072891A1 (en) 1991-07-03
AU7242491A (en) 1991-07-24
JPH05502032A (ja) 1993-04-15
JP2610740B2 (ja) 1997-05-14
AU644139B2 (en) 1993-12-02

Similar Documents

Publication Publication Date Title
US5705163A (en) Target-specific, cytotoxic, recombinant pseudomonas exotoxin
Chaudhary et al. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity.
US5328984A (en) Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5563046A (en) Fusion polypeptides and proteins
CN101432296B (zh) 聚乙二醇化的突变的肉毒梭菌毒素
US5914254A (en) Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5082927A (en) Selectively cytotoxic IL-4-PE40 fusion protein
CA2298015C (en) Production of erythropoietin by endogenous gene activation
US5874247A (en) Protein disulfide isomerase and method of using
US7887801B2 (en) Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
CA2189774A1 (en) Recombinant hk2 polypeptide
Prior et al. Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol
JPH08506586A (ja) 殺菌性／浸透性が向上した安定なタンパク質生成物およびそれを含む薬剤組成物
CA1339894C (en) Fusion proteins with a eukaryotic ballast portion
CA2072891C (en) Pseudomonas exotoxin fusion proteins having carboxyl alterations with increased cytotoxicity
RU2144957C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
CN100436581C (zh) 人干扰素α的表达和分泌载体及通过使用这种载体产生人干扰素α的方法
Canals et al. Production of engineered human pancreatic ribonucleases, solving expression and purification problems, and enhancing thermostability
JP2012511309A (ja) Ｅｃ−ｓｏｄのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
CA2082226A1 (en) Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
CA2240392C (en) Multimer forms of interleukin-16 (il-16), process for the preparation and use thereof
CN113354738B (zh) 融合毒素VEGF165b/mGEL及其编码基因与应用
JP2019500338A (ja) 抗菌活性を有する新規ペプチド及びペプチド中におけるｌ型残基をｄ型アミノ酸に変換することができる新規酵素
JPH0638787A (ja) 可溶性エリスロポエチン受容体蛋白質、およびそのアミノ酸配列をコードする遺伝子
JPH0361494A (ja) ムテイン，ｄｎａおよびその用途

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed